Purpose Liver metastasis (LM) is common in non-small cell lung cancer (NSCLC), and
always predicted worse outcomes with no effective therapy. We aimed to evaluate the effects …

Liver metastasis is common in advanced small cell lung cancer (SCLC). There is no
evidence‐proven treatment beyond the second line in patients with SCLC and liver …

Background Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently
developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The …

Purpose The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase
inhibitor, administered as third-line or further treatment prolonged progression-free survival …

Background Anlotinib has been shown to prolong progression‐free survival (PFS) and
overall survival (OS) for non‐small cell lung cancer (NSCLC). Herein we sought to analyze …

Aims Combination of anti-angiogenesis therapy and immunotherapy has showed synergistic
effects in non-small cell lung cancer (NSCLC). The aim of this retrospective study was to …

Background This real‐world study assessed the efficacy and toxicity of anlotinib as salvage
treatment in Chinese patients with advanced non‐small cell lung cancer (NSCLC). Methods …

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer
and its incidence seriously affects human health. The purpose of this study was to evaluate …

Objective: To evaluate the efficacy and safety of anlotinib in patients with advanced non-
small cell lung cancer (NSCLC). Methods: Patients with stage ⅢB/Ⅳ NSCLC who …

Objective: To retrospectively analyze the clinical efficacy, safety and the main factors
affecting the prognosis of anlotinib hydrochloride in the treatment of advanced primary liver …